The Heart of Abbott Laboratories (ABT)’s Future

Even as the stent market’s on the decline because of pricing pressures, signs point to it picking back up and exceeding $6 billion worldwide by 2015. That’s just in time for Abbott to take advantage if it can pick up FDA approval for Absorb, ensuring that its substantial market share in this industry — Abbott controlled 31% of the stent market  in 2010 — won’t go away.

If it can hang onto its market share, Abbott will see strong growth out of this business if the industry picks up as planned.

Looking for growth
Even with the U.S. stent market in retreat today, Abbott’s still managed to boost its vascular business’ sales. When the industry returns, the company will be primed to capitalize — and investors will be the big winners. Still, vascular products are only one part of Abbott’s portfolio in its post-pharmaceutical life; this company will have to find growth in other areas, as well, to succeed.

The article The Heart of Abbott’s Future originally appeared on Fool.com and is written by Dan Carroll.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.